Drilon, Alexander

selected publications

MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 39
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer. Future oncology (London, England). 2020 Academic Article GET IT
Times cited: 6
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. Cancer discovery. 2020 Academic Article GET IT
Times cited: 40
Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series. The oncologist. 2020 Academic Article GET IT
Times cited: 35
NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Information Resource GET IT
The METeoric rise of MET in lung cancer. Cancer. 2020 Information Resource GET IT
Times cited: 6
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. The New England journal of medicine. 2020 Academic Article GET IT
Times cited: 574
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. The New England journal of medicine. 2020 Academic Article GET IT
Times cited: 66
Clinical implications of drug-induced liver injury in early-phase oncology clinical trials. Cancer. 2020 Academic Article GET IT
ROS1-dependent cancers - biology, diagnostics and therapeutics. Nature reviews. Clinical oncology. 2020 Information Resource GET IT
Times cited: 14
CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib. JCO precision oncology. 2020 Academic Article GET IT
Times cited: 20
Progresses Toward Precision Medicine in RET-altered Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Information Resource GET IT
Times cited: 4
An umbrella approach to test lung cancer therapies. Nature. 2020 Article GET IT
Times cited: 1
COVID-19 in patients with lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Academic Article GET IT
Times cited: 197
MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nature reviews. Clinical oncology. 2020 Information Resource GET IT
Times cited: 203
Characterization of on-target adverse events caused by TRK inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Academic Article GET IT
Times cited: 44
Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Academic Article GET IT
Times cited: 20
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 16
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 37
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. The Lancet. Oncology. 2020 Academic Article GET IT
Times cited: 705
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures. Cancer treatment reviews. 2020 Information Resource GET IT
Times cited: 96
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2020 Academic Article GET IT
Times cited: 211
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 118
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. The Lancet. Oncology. 2019 Academic Article GET IT
Times cited: 375
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. The Lancet. Oncology. 2019 Academic Article GET IT
Times cited: 1202
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature medicine. 2019 Academic Article GET IT
Times cited: 138
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. JAMA oncology. 2019 Academic Article GET IT
Times cited: 417
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung cancer (Amsterdam, Netherlands). 2019 Information Resource GET IT
Times cited: 165
Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers. Cancer. 2019 Academic Article GET IT
Times cited: 57
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. The Lancet. Oncology. 2019 Academic Article GET IT
Times cited: 259
Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature medicine. 2019 Academic Article GET IT
Times cited: 162
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2019 Academic Article GET IT
Times cited: 409
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 951
Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology. JCO precision oncology. 2019 Academic Article GET IT
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Academic Article GET IT
Times cited: 125
Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 42
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. Journal of the National Cancer Institute. 2019 Academic Article GET IT
Times cited: 98
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 10
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 113
Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors. 2019 GET IT
Times cited: 15
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung cancer (Amsterdam, Netherlands). 2019 Academic Article GET IT
Times cited: 81
Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 50
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 324
Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. Cold Spring Harbor molecular case studies. 2019 Academic Article GET IT
Times cited: 23
The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement. Human pathology. 2019 Academic Article GET IT
Times cited: 39
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. European journal of cancer. 2019 Academic Article GET IT
Times cited: 71
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. Cancer research. 2019 Academic Article GET IT
Times cited: 115
Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Academic Article GET IT
Times cited: 66
NTRK fusion-positive cancers and TRK inhibitor therapy. Nature reviews. Clinical oncology. 2018 Information Resource GET IT
Times cited: 1049
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. Cancer discovery. 2018 Academic Article GET IT
Times cited: 95
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 91
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 244
Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers. JCO precision oncology. 2018 Academic Article GET IT
Times cited: 88
Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma. JCO precision oncology. 2018 Academic Article GET IT
Times cited: 3
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 255
Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO precision oncology. 2018 Academic Article GET IT
Times cited: 199
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Therapeutics and clinical risk management. 2018 Review GET IT
Times cited: 90
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Academic Article GET IT
Times cited: 153
CT features of HER2-mutant lung adenocarcinomas. Clinical imaging. 2018 Information Resource GET IT
Times cited: 8
Learning All That We Can From MyPathway. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Article GET IT
Times cited: 1
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. The American journal of surgical pathology. 2018 Academic Article GET IT
Times cited: 181
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 41
Tumor-Agnostic Drug Development. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2018 Academic Article GET IT
Times cited: 33
Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. Cancer discovery. 2018 Academic Article GET IT
Times cited: 152
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 2083
HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Academic Article GET IT
Times cited: 594
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nature reviews. Clinical oncology. 2017 Information Resource GET IT
Times cited: 253
RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 51
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. The American journal of surgical pathology. 2017 Academic Article GET IT
Times cited: 376
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nature reviews. Clinical oncology. 2017 Information Resource GET IT
Times cited: 123
Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 52
Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target. Nature communications. 2017 Academic Article GET IT
Times cited: 56
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. Cancer discovery. 2017 Academic Article GET IT
Times cited: 344
Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?. Translational lung cancer research. 2017 Editorial Article GET IT
Times cited: 6
Targeting RET-rearranged lung cancers with multikinase inhibitors. Oncoscience. 2017 Editorial Article GET IT
The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers. OncoTargets and therapy. 2017 Information Resource GET IT
Times cited: 51
Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy. Current oncology reports. 2017 Information Resource GET IT
Times cited: 33
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer discovery. 2017 Academic Article GET IT
Times cited: 492
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 298
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Investigational new drugs. 2017 Academic Article GET IT
Times cited: 12
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer discovery. 2017 Academic Article GET IT
Times cited: 663
Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 65
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 374
Targeted therapy outcomes in RET-rearranged lung cancers: drug or driver?. The Lancet. Respiratory medicine. 2016 Article GET IT
Times cited: 1
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Information Resource GET IT
Times cited: 303
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Academic Article GET IT
Times cited: 98
MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 42
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 359
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. Cancer. 2016 Academic Article GET IT
Times cited: 10
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Academic Article GET IT
Times cited: 82
A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Academic Article GET IT
Times cited: 50
Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. JAMA oncology. 2015 Article GET IT
Times cited: 215
From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?. Lung cancer (Amsterdam, Netherlands). 2015 Academic Article GET IT
Times cited: 23
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 2015 Academic Article GET IT
Times cited: 100
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 17
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer discovery. 2015 Academic Article GET IT
Times cited: 490
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 236
MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 117
A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 34
RET mutations in neuroendocrine tumors: including small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Editorial Article GET IT
Times cited: 11
Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Lung cancer (Amsterdam, Netherlands). 2014 Academic Article GET IT
Times cited: 50
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer discovery. 2013 Academic Article GET IT
Times cited: 436
Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 168
Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. The Lancet. Oncology. 2012 Information Resource GET IT
Times cited: 142
Systemic approaches for multifocal bronchioloalveolar carcinoma: is there an appropriate target?. Oncology (Williston Park, N.Y.). 2010 Information Resource GET IT
Times cited: 5
Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy. Cancer. 2008 Academic Article GET IT
Times cited: 123

VIVO Weill Cornell Medical College

Alexander Drilon Associate Professor of Medicine

Publications

selected publications

Contact

full name

Phone

Publications

selected publications

Contact

full name